

Kinase KING

Kinase Inhibitors for the Next Generation



A platform for rapid development of highly selective next-generation protein kinase inhibitors.

Background

Protein kinase inhibitors (PKIs) are a class of drugs that block the activity of protein kinases, which are enzymes that play a central role in many cellular processes. The market for PKIs is growing rapidly, with sales projected to reach \$50 billion by 2020.

1. The first generation of PKIs was developed in the 1990s and 2000s. These drugs were often non-selective and had a high risk of side effects.
2. The second generation of PKIs was developed in the 2010s. These drugs were more selective and had a lower risk of side effects.

Technology

The Kinase KING platform is a novel technology for the development of highly selective PKIs. It is based on a novel approach to the design of PKIs, which allows for the rapid development of highly selective inhibitors for a wide range of protein kinases.

The Kinase KING platform is a novel technology for the development of highly selective PKIs. It is based on a novel approach to the design of PKIs, which allows for the rapid development of highly selective inhibitors for a wide range of protein kinases.

Major advantages

- Highly selective
- Rapid development
- Low risk of side effects
- Broad range of protein kinases
- Novel approach to design



UniServices

L 10, 49 S m S ,